Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Plus S-1 and Bevacizumab in Advanced Colorectal Cancer
NCT02487992Phase 2Active, not recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Jul 2015
- Primary completion
- Jul 2043
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
A Phase 2 trial of unmodified CIK in colorectal cancer (CRC), sponsored by Changzhou First People's Hospital. Started Jul 2015; status: active, not recruiting.
02
Drugs
unmodified CIK
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02487992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487992.